- Home
- PASG vs CYCC Comparison
PASG vs CYCC Comparison
Compare PASG & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- CYCC
- Stock Information
- Founded
- PASG 2017
- CYCC 1992
- Country
- PASG United States
- CYCC Malaysia
- Employees
- PASG N/A
- CYCC N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- CYCC Health Care
- Exchange
- PASG Nasdaq
- CYCC Nasdaq
- Market Cap
- PASG 20.3M
- CYCC 17.5M
- IPO Year
- PASG 2020
- CYCC N/A
- Fundamental
- Price
- PASG $7.00
- CYCC $6.37
- Analyst Decision
- PASG Strong Buy
- CYCC
- Analyst Count
- PASG 4
- CYCC 0
- Target Price
- PASG $59.25
- CYCC N/A
- AVG Volume (30 Days)
- PASG 34.7K
- CYCC 82.6K
- Earning Date
- PASG 11-12-2025
- CYCC 11-11-2025
- Dividend Yield
- PASG N/A
- CYCC N/A
- EPS Growth
- PASG N/A
- CYCC N/A
- EPS
- PASG N/A
- CYCC N/A
- Revenue
- PASG N/A
- CYCC $10,000.00
- Revenue This Year
- PASG N/A
- CYCC $137.21
- Revenue Next Year
- PASG N/A
- CYCC N/A
- P/E Ratio
- PASG N/A
- CYCC N/A
- Revenue Growth
- PASG N/A
- CYCC N/A
- 52 Week Low
- PASG $5.12
- CYCC $3.08
- 52 Week High
- PASG $26.60
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- PASG 50.90
- CYCC 37.28
- Support Level
- PASG $6.86
- CYCC $5.92
- Resistance Level
- PASG $7.29
- CYCC $8.82
- Average True Range (ATR)
- PASG 0.47
- CYCC 0.58
- MACD
- PASG -0.03
- CYCC -0.04
- Stochastic Oscillator
- PASG 34.58
- CYCC 15.52
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.